Proteasome inhibitors: all 957 studies that test it
Page 8 of 10. Open to participants first (61), then studies with results posted, then the rest; newest registration first within each.
- Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell LeukemiaCompletedNCT01372540Phase 1
- Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma PatientsCompletedNCT01346787Phase 2
- Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell LymphomaCompletedNCT01336920Phase 1
- Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell LeukemiaStatus unknownNCT01328236Phase 2
- A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With BortezomibCompletedNCT01324596Phase 3
- Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell LymphomaStatus unknownNCT01322776Phase 1/2
- Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT01301807Phase 1
- Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and EtoposideTerminatedNCT01300793Phase 1
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple MyelomaActive, not recruitingNCT01297764Phase 1/2
- Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)CompletedNCT01279694Phase 1/2
- Study of Carfilzomib and Vorinostat for Relapsed or Refractory LymphomaCompletedNCT01276717Phase 1
- Study of Bortezomib +HSCT in Primary Systemic Amyloidosis (AL)CompletedNCT01273844Not applicable
- Evaluating the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 StudyStatus unknownNCT01255527Phase 1/2
- Efficacy Study of PAD and TAD in Newly Diagnosed Multiple MyelomaStatus unknownNCT01249690Phase 4
- Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)CompletedNCT01212380Phase 1
- Frontline Therapy in de Novo Multiple Myeloma Patients Under 65CompletedNCT01206205Phase 2
- Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 YearsCompletedNCT01191060Phase 3
- Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT01174888Phase 1
- A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or LymphomaCompletedNCT01171092Early Phase 1
- Velcade for Proliferative Lupus NephritisWithdrawnNCT01169857Phase 4
- Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple MyelomaCompletedNCT01168804Phase 2
- Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic CancerCompletedNCT01164709Phase 1
- Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple MyelomaCompletedNCT01163357Phase 1
- Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic LeukemiaWithdrawnNCT01162031Phase 2
- Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)Status unknownNCT01158105Phase 2
- Carfilzomib in Patients With Relapsed Acute Myeloid or Acute Lymphoblastic LeukemiaCompletedNCT01137747Phase 1
- VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)Status unknownNCT01134484Phase 3
- Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid TumorsCompletedNCT01129349Phase 1
- Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell LymphomaCompletedNCT01129180Phase 1
- Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01127009Phase 1
- Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MMCompletedNCT01114282Phase 1
- Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)Status unknownNCT01114048Phase 2
- Study of Induction Treatment With Velcade and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal FailureCompletedNCT01084837Phase 2
- An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant MelanomaCompletedNCT01078961Phase 1
- Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT01074411Phase 1
- Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma PatientsCompletedNCT01063179Phase 3
- S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaWithdrawnNCT01055301Phase 2
- Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's MacroglobulinemiaCompletedNCT01046006Phase 2
- Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple MyelomaCompletedNCT01045681Phase 2
- A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01038388Phase 1
- Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent TherapyTerminatedNCT01023880Phase 1/2
- Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi SarcomaCompletedNCT01016730Phase 1
- Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal MesotheliomaStatus unknownNCT00996385Phase 2
- Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple MyelomaWithdrawnNCT00995059Phase 1/2
- Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and LymphomaCompletedNCT00994500Phase 1
- Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma PatientsTerminatedNCT00984828Phase 2/3
- Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple MyelomaCompletedNCT00972712Phase 1
- Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT00963274Phase 1
- Study of Erlotinib in Combination With BortezomibCompletedNCT00895687Phase 1
- Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior TherapyActive, not recruitingNCT00871013Phase 2
- UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete RemissionActive, not recruitingNCT00869232Phase 2
- Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCTCompletedNCT00861250Phase 2/3
- Relapsed and/or Refractory Non-Hodgkin Lymphoma StudyWithdrawnNCT00837174Phase 2
- Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms MacroglobulinemiaCompletedNCT00832234Phase 2
- PAD. ICORG 05-01, V11CompletedNCT00814541Phase 2
- Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström MacroglobulinemiaCompletedNCT00777738Phase 2
- Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving RadioimmunotherapyCompletedNCT00777114Phase 1
- Study of Temsirolimus, Topotecan, and BortezomibCompletedNCT00770731Phase 1
- A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma PatientsCompletedNCT00752518Phase 1/2
- Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00744354Phase 1
- Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaStatus unknownNCT00742404Phase 2
- UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk MyelomaActive, not recruitingNCT00734877Phase 3
- S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom MacroglobulinemiaWithdrawnNCT00723658Phase 2
- Natural Killer Cells and Bortezomib to Treat CancerCompletedNCT00720785Phase 1
- A Phase I Trial of Bortezomib and SunitinibCompletedNCT00720148Phase 1
- Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung CancerTerminatedNCT00714246Phase 1
- A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With BortezomibWithdrawnNCT00706953Phase 2
- Decitabine and Bortezomib in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00703300Phase 1
- A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) TransplantationCompletedNCT00670423Phase 1
- Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid TumorsCompletedNCT00667641Phase 1
- NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or LymphomaCompletedNCT00667082Phase 1
- Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple MyelomaCompletedNCT00652041Phase 4
- Velcaflagida in Relapsed or Refractary Acute Myeloid LeukemiaCompletedNCT00651781Phase 1/2
- Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory NeuroblastomaCompletedNCT00644696Phase 1
- Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT)CompletedNCT00642395Phase 2
- A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's LymphomaCompletedNCT00636311Phase 2
- Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced MalignanciesCompletedNCT00629473Phase 1
- Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck CancerCompletedNCT00629226Phase 1
- Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT00624936Phase 1
- Bortezomib and Cetuximab in Treating Patients With Advanced Solid TumorsCompletedNCT00622674Phase 1
- Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid TumorsCompletedNCT00620295Phase 1
- Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing RegimensWithdrawnNCT00610792Phase 2
- Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin LymphomaCompletedNCT00598169Phase 1
- Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT00590603Phase 1
- Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue SarcomaCompletedNCT00580320Phase 1
- A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With MyelodysplasiaCompletedNCT00580242Phase 1
- A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD)WithdrawnNCT00577668Phase 2
- Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin's LymphomasCompletedNCT00572637Phase 1
- Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple MyelomaCompletedNCT00570180Phase 2
- Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00568880Phase 1
- MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative ConditioningCompletedNCT00564200Phase 2
- A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma PatientsCompletedNCT00561743Phase 2
- Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to TreatmentCompletedNCT00544284Phase 1
- Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid TumorsCompletedNCT00541359Phase 1
- A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple MyelomaWithdrawnNCT00516191Phase 1/2
- Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLCStatus unknownNCT00516100Phase 1/2
- A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell TransplantTerminatedNCT00515138Early Phase 1
- A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple MyelomaCompletedNCT00514371Phase 2/3
- Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaCompletedNCT00513955Phase 2
- Bortezomib in Treating Patients With Malignant Pleural MesotheliomaCompletedNCT00513877Phase 2